Related references
Note: Only part of the references are listed.Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Dominik Paul Modest et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies
Daniele Rossini et al.
EUROPEAN JOURNAL OF CANCER (2022)
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis
Richard Adams et al.
CANCER TREATMENT REVIEWS (2021)
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study
Raymond Hugo Henderson et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
The Role of Maintenance Strategies in Metastatic Colorectal Cancer A Systematic Review and Network Meta-analysis of Randomized Clinical Trials
Mohamad Bassam Sonbol et al.
JAMA ONCOLOGY (2020)
Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis?
Eduard Vrdoljak et al.
EUROPEAN JOURNAL OF CANCER (2020)
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
Amit Sud et al.
LANCET ONCOLOGY (2020)
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study
Alvina G. Lai et al.
BMJ OPEN (2020)
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
Filippo Pietrantonio et al.
JAMA ONCOLOGY (2019)
Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update
Julia Mann et al.
CURRENT COLORECTAL CANCER REPORTS (2019)
Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer
Jonathan M. Loree et al.
CLINICAL COLORECTAL CANCER (2018)
First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.
Filippo Pietrantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer
M. D. Franken et al.
EUROPEAN JOURNAL OF CANCER (2017)
Description of the health problem
Nicola Huxley et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
N. Boeckx et al.
ANNALS OF ONCOLOGY (2017)
Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
E. J. van Helden et al.
CANCER AND METASTASIS REVIEWS (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing et al.
LANCET ONCOLOGY (2016)
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Kamil A. Lipinski et al.
TRENDS IN CANCER (2016)
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M. Schirripa et al.
BRITISH JOURNAL OF CANCER (2015)
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H. J. Simkens et al.
LANCET (2015)
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Susanna Hegewisch-Becker et al.
LANCET ONCOLOGY (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (vol 21, pg 795, 2015)
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
Harpreet Wasan et al.
LANCET ONCOLOGY (2014)
Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
Martin Hoyle et al.
VALUE IN HEALTH (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Richard A. Adams et al.
LANCET ONCOLOGY (2011)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
Aimery de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years
A. de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial
TS Maughan et al.
LANCET (2003)
Share Paper
